USA flag logo/image

An Official Website of the United States Government

Genevax HIV AIDS Vaccine--Phase I

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
24774
Program Year/Program:
1994 / SBIR
Agency Tracking Number:
24774
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Apollon, Inc.
1 Great Valley Parkway Malvern, PA 19355
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1994
Title: Genevax HIV AIDS Vaccine--Phase I
Agency: HHS
Contract: 1 R43 AI35499-1A1,
Award Amount: $74,996.00
 

Abstract:

Our efforts recently yielded a report describing the successful immunization of mice against theHIV-1 coat protein (gp160) using the technique of genetic vaccination. Animals were directly inoculatedwith DNA containing the HIV-1 gp160 gene, resulting in humoral and cellular immunity to the HIVgp160. More recent work has demonstrated protection from a normally lethal cell challenge with amurine myeloma expressing gp160. For the present application, various plasmids will be constructed,used alone or modified for inoculation, that will induce an immune response directed against either SIVor HIV-1 gene products. Plasmids will be modeled after the one used in the successful gp160 HIVexperiments; however, the genes for many of the SIV and HIV proteins will be incorporated into theplasmids. Construction will be accomplished using standard recombinant DNA cloning techniques.Several of the HIV constructs or modified constructs will be designed to be safely compatible withhuman inoculation in anticipation of their use in human clinical trials. The immediate objectives of thisPhase I study will be (i) construction of the plasmids, (ii) evaluation of the levels of protein expressionin human rhabdomyosarcoma and murine myeloma cells that have been transfected with the constructsof interest, and (iii) evaluation of immunogenicity using mice and guinea pigs to provide a logical basisfor the selection of plasmids for further development as components of a genetic vaccine for HIV-1(GENEVAX-HIV). The long-term goal of this work will be the development and commercialization ofGENEVAX-HIV for the possible treatment or prophylaxis of HIV-infected persons.

Principal Investigator:

Leslie Coney
2156479452

Business Contact:

Small Business Information at Submission:

Apollon, Inc.
1 Great Valley Parkway Malvern, PA 19355

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No